Stamford-based Loxo Oncology, which is developing cancer treatments, announced this week that it had gained Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its Loxo-292 drug.

“We look forward to working with FDA to streamline the development of Loxo-292 in the two patient populations that have comprised the bulk of our initial clinical trial enrollment,” Loxo CEO Josh Bilenker said in a statement. “Given the many available therapies for non-small-cell lung cancer and medullary thyroid cancer, we are pleased that Loxo-292 has shown encouraging data in ‘refractory’ patients and hope to demonstrate the full potential of this treatment in additional populations over time.”